SCHEMBL352986

SCHEMBL352986

O=C(OC(Cc1ccccc1)C(=O)O)C(O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SRR Q9GZT4 2/20 0.59
ACE P12821 1/20 0.58
PPARG P37231 16/20 0.51
PPARA Q07869 14/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28278431 1.00 SRR (0.59) SRRACEPPARGPPARA
SCHEMBL8323546 0.87 SLC7A5 (0.49) SRRACEPPARGPPARA
SCHEMBL8953447 0.85 PPARG (0.54) SRRACEPPARGPPARA
SCHEMBL8361809 0.85 SRR (0.46) SRRACEPPARGPPARA
SCHEMBL8953478 0.84 PPARG (0.57) SRRACEPPARGPPARA
SCHEMBL10407749 0.83 SRR (0.59) SRRACEPPARGPPARA
SCHEMBL8953769 0.82 PPARA (0.58) PPARGPPARA
SCHEMBL8953590 0.82 ALDH1A1 (0.42) SRRACEPPARGPPARA
SCHEMBL9554385 0.81 SRR (0.57) SRRACEPPARGPPARA
SCHEMBL8953540 0.81 PPARA (0.50) ACEPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120093737-A1 LIGHT-ABSORBING COMPOSITIONS AND METHODS OF USE ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC. 2012-04-19 US disclosed
US-20120076842-A1 COSMETIC USE OF TYR-ARG DIPEPTIDE TO COMBAT CUTANEOUS SAGGING SEDERMA (FR) 2012-03-29 US disclosed
EP-2419076-A2 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES Sederma (FR) 2012-02-22 EP disclosed
US-20120028916-A1 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES SEDERMA (FR) 2012-02-02 US disclosed
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES SEDERMA (FR) 2012-01-19 US disclosed
EP-2382231-A2 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMOPHARMACEUTICAL USES Sederma (FR) 2011-11-02 EP disclosed
EP-2382230-A2 KXK-PEPTIDE COMPOSITIONS FOR COSMETIC AND DERMO-PHARMACEUTIC USES Sederma (FR) 2011-11-02 EP disclosed
US-20110250276-A1 Cosmetic Composition Containing Acetylated Oligoglucuronans SEDERMA, S.A.S. (FR) 2011-10-13 US disclosed
EP-2367852-A1 COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS Sederma (FR) 2011-09-28 EP disclosed
EP-2046283-B1 COMPOSITION COMPRISING SARSASAPOGENIN SEDERMA SA (FR) 2011-03-16 EP disclosed
US-20110045036-A1 Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle SEDERMA (FR) 2011-02-24 US disclosed
US-20110033507-A1 Polypeptides KXK and Their Use SEDERMA (FR) 2011-02-10 US disclosed
US-20110002865-A1 MOISTURIZING COSMETIC COMPOSITION COMPRISING A COMBINATION OF HOMARINE AND ERYTHRITOL SEDERMA, S.A.S. (FR) 2011-01-06 US disclosed
US-5514773-A PARASITICIDES, ANTHELMINTICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014887-A1 NEW COMPOUNDS, IN PARTICULAR PEPTIDES, COMPOSITIONS COMPRISING THEM AND COSMETIC AND DERMO-PHARMACEUTICAL USES CUTA, PLOD3, MC1R SRR 292/4885ACE 4562/4885PPARG 838/4885
US-20110033507-A1 Polypeptides KXK and Their Use NPR3, NGLY1, NPR1 SRR 1130/4885ACE 4725/4885PPARG 4217/4885
US-20120076842-A1 COSMETIC USE OF TYR-ARG DIPEPTIDE TO COMBAT CUTANEOUS SAGGING ARGLU1, CUTA, ARG1 SRR 905/4885ACE 3898/4885PPARG 2053/4885
US-20110045036-A1 Cosmetic Compositions Comprising at Least One Peptide with at Least One Immobilized Aromatic Cycle TYR, XPA, MC1R SRR 1325/4885ACE 2023/4885PPARG 2127/4885
US-20110002865-A1 MOISTURIZING COSMETIC COMPOSITION COMPRISING A COMBINATION OF HOMARINE AND ERYTHRITOL AQP1, CUTA, AQP3 SRR 342/4885ACE 2508/4885PPARG 4423/4885
US-20110250276-A1 Cosmetic Composition Containing Acetylated Oligoglucuronans GLA, OGA, CUTA SRR 4601/4885ACE 3614/4885PPARG 272/4885
US-20120028916-A1 COSMETIC COMPOSITIONS COMPRISING ORIDONIN AND NEW COSMETIC USES DPM1, MC1R, SLTM SRR 314/4885ACE 4657/4885PPARG 451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.